Phase II trial of gemcitabine-carboplatin-paclitaxel as neoadjuvant chemotherapy for operable non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 1, Issue 2, 2006, Pages 135-140

  Abratt, Raymond P ^a   Lee, Jung Sin ^b   Han, Ji Youn ^c   Tsai, Chun Ming ^d   Boyer, Michael ^e   Mok, Tony ^f   Kim, Sang We ^b   Lee, Jin Soo ^c   Brnabic, Alan J M ^g   Reece, William H H ^g   Lehnert, Manfred ^h  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b University of Ulsan College of Medicine   (South Korea)

^c National Cancer Center   (South Korea)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^e ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^f CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^g Clinical Outcomes and Research Institute   (Australia)

^h Eli Lilly Asian Operations   (Hong Kong)

Author keywords

Neoadjuvant chemotherapy; Non small cell lung cancer; Triplet regimen

Indexed keywords

ANTIHISTAMINIC AGENT; CARBOPLATIN; CIMETIDINE; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IFOSFAMIDE; MITOMYCIN; PACLITAXEL; RANITIDINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; RIBONUCLEOTIDE REDUCTASE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURGERY; CELL VIABILITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; HISTOLOGY; HUMAN; INFECTION; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR CELL; ADJUVANT THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG COMBINATION; FOLLOW UP; HOSPITALIZATION; LUNG TUMOR; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PACLITAXEL; RIBONUCLEOTIDE REDUCTASES; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

EID: 34247844375     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01243894-200602000-00006     Document Type: Article

References (32)

1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of twenty-five major cancers in 1990. Int J Cancer 1999;80:827-841.
2. Pisani P, Parkin DM, Bray FI, et al. Estimates of the worldwide mortality from twenty-five major cancers in 1990. Int J Cancer 1999;83:18-29.
3. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111:1710-1717.
4. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-360.
5. Pisters KMW, Le Chevalier T. Adjuvant chemotherapy in completely resected non-small-cell lung cancer. J Clin Oncol 2006;23:3270-3278.
6. Roth JA, Fosella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 1994;86:673-680.
7. Roth JA, Atkinson EN, Fossella F, et al. Long-term follow-up of patients enrolled in a randomised trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 1998;21:1-6.
8. Rosell R, Gómez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994;330:153-158.
9. Rosell R, Gómez-Codina J, Camps C, et al. Presectional chemotherapy in stage IIIA non-small-cell lung cancer: A 7-year assessment of a randomised controlled trial. Lung Cancer 1999;47:7-14.
10. Depierre A, Milleron B, Moro-Sibilot D, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 2002;20:247-253.
11. van Zandwijk N, Smit EF, Kramer GWP, et al. Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung cancer: A Phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955). J Clin Oncol 2000;18:2658-2664.
12. Santo A, Pedersini R, Pasini F, et al. A phase II study of induction chemotherapy with gemcitabine (G) and cisplatin (P) in locally advanced non-small cell lung cancer: Interim analysis. Lung Cancer 2001;34:S15-S20.
13. Migliorino MR, De Marinis F, Nelli F, et al. A 3-week schedule of gemcitabine plus cisplatin as induction chemotherapy for stage III non-small cell lung cancer. Lung Cancer 2002;35:319-327.
14. Betticher DC, Hsu Schmitz SF, Tötsch M, et al. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer. J Clin Oncol 2003;21:1752-1759.
15. Cappuzzo F, Selvaggi G, Gregorc V, et al. Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable stage IIIA-bulky N2 and stage IIIB nonsmall cell lung carcinoma. Cancer 2003;98:128-134.
16. O'Brien MER, Splinter T, Smit EF, et al. Carboplatin and paclitaxel (Taxol) as an induction regimen for patients with biopsy-proven stage IIIA non-small cell lung cancer: An EORTC phase II study (EORTC 08958). Eur J Cancer 2003;39:1416-1422.
17. Delbaldo C, Michiels S, Syz N, et al. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: A meta-analysis. JAMA 2004;292:470-484.
18. Frasci G, Panza N, Comella P, et al. Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small cell lung cancer: A phase I-II study. J Clin Oncol 1999;17:2316-2325.
19. Hainsworth JD, Burris HA III Erland JB, et al. Phase I/II trial of paclitaxel by 1-hour infusion, carboplatin and gemcitabine in the treatment of patients with advanced nonsmall cell lung carcinoma. Cancer 1999;85:1269-1276.
20. Sorensen JB, Stenbygaard LE, Dombernowsky P, et al. Paclitaxel, gemcitabine, and cisplatin in non-resectable non-small-cell lung cancer. Ann Oncol 1999;10:1043-1049.
21. Kelly K, Mikhaeel-Kamel N, Pan Z, et al. A phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced nonsmall cell lung cancer. Clin Cancer Res 2000;6:3474-3479.
22. Rodriguez J, Cortes J, Emiliano C, et al. Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma: A Phase II study. Cancer 2000;89:2622-2629.
23. Cappuzzo F, De Marinis F, Nelli F, et al. Phase II study of gemcitabine-cisplatin-paclitaxel triplet as induction chemotherapy in inoperable, locally-advanced non-small cell lung cancer. Lung Cancer 2003;42:355-361.
24. De Marinis F, Nelli F, Migliorino MR, et al. Gemcitabine, paclitaxel, and cisplatin as induction chemotherapy for patients with biopsy-proven stage IIIA(N2) nonsmall cell lung carcinoma. Cancer 2003;98:1707-1715.
25. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-1756.
26. National Cancer Institute. Common toxicity criteria (version 2). Bethesda, MD: Division of Cancer Treatment and Diagnosis, National Cancer Institute, 1999. Available at: http://ctep.info.nih.gov/ctc3/ctc.htm. Accessed April 23, 2005.
27. Pisters KM, Ginsberg RJ, Giroux DJ, et al. Induction chemotherapy before surgery for early-stage lung cancer: A novel approach - Bimodality Lung Oncology Team. J Thorac Cardiovasc Surg 2000;119:429-439.
28. Pisters K, Vallieres E, Bunn P, et al. S990: A phase III trial of surgery alone or surgery plus preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): Preliminary results (Abstract). Proc Am Soc Clin Oncol 2006;23:LBA7012.
29. Hotta K, Matsuo K, Ueoka H, et al. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004;22:3852-3859.
30. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003. J Clin Oncol 2004;22:330-353.
31. Go RS, Adjei AA. Review of comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999;17:409-422.
32. Zatloukal P, Petruzělka L, Zemanova M, et al. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: A phase III randomized trial. Lung Cancer 2003;41:321-331.